'Quick Fix' Not The Answer: Drug-Development Process Already Subject to Oversight
More like this
- A Conversation with John Abramson, MD: Is It Time To Create a 'Fed Board' To Oversee Clinical Research?
- An Interview with David Nash, M.D., M.B.A.
- OTC Status for Low-Dose Lovastatin Would Have Widespread Implications
- A Conversation with David B. Nash, MD, MBA: Steadily, We Move Toward the Primacy of Outcomes
- Prescription Drug Reimportation: Panacea or Problem?